Abstract
Beta-blockers have played an important role in the treatment of many cardiovascular diseases, but their role in the treatment of hypertension has been controversial. Some recent guidelines such as JNC 8 no longer consider beta-blockers a first-line treatment for hypertension, except in resistant hypertension, hypertension accompanied by cardiovascular disease, or compelling indications (heart failure, coronary artery disease). This article analyzes why beta-blockers are no longer chosen for primary prevention in hypertensive patients, based on clinical trials and meta-analyses (LIFE, ASCOT-BPLA, Cochrane...), the limitations of atenolol, and the current role of beta-blockers in the treatment of hypertension.